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RHEUMATOID arthritis (RA) patients are at higher risks
of  bacterial  infection  than  healthy  subjects.  Poly-
morphonuclear leukocytes (PMN) are the first line of
nonspecific cellular defence against these infections.
We  tested  the  hypothesis  that  abnormal  directed
migration  of  PMN  may  be  one  reason  for  the
increased infection rate of RA patients.  PMN migra-
tion was investigated in 68 peripheral blood samples
of  15  RA  patients  compared  with  64  samples  of
healthy  controls  in  a  novel  whole  blood  in  vitro
membrane filter assay. The migration of PMNs from
RA  patients  and  controls  was  stimulated  using  the
bacterial chemoattractant N-formyl-methionyl-leucyl-
phenylalanine (fMLP).  Unstimulated  PMN migration
of RA patients was increased compared with healthy
controls as measured by the following parameters: (a)
absolute number of migrant PMNs (1954 ± 87 vs. 1238
±  58  PMN/mm
2),  (b)  percentage  of  PMNs  migrated
into the filter (total migration index, TMI) (28.6 ± 0.9
vs. 24.0 ± 0.8 %), (c) the distance half the migrating
PMNs  had  covered  (distribution  characteristic,  DC)
(22.6 ± 1.1 vs. 16.1 ± 0.6 mm) and (d) the product of
TMI  and  DC  (neutrophil  migratory  activity,  NMA)
(669.0 ± 45.0 vs. 389.0 ± 18.9). fMLP stimulated PMNs
of RA patients showed defective migration compared
to unstimulated samples as shown by (a) a reduced
number of migrant PMNs (1799 ± 93 PMN/mm
2), (b)
lower TMI  (26.1 ± 0.9 %),  (c)  unremarkable altered
distribution  characteristic  (22.9  ±  0.8 mm)  and  (d)
significant reduced migratory activity (600.0 ± 30.0).
Our data suggest that the high incidence of infections
in  RA  patients  may  partly  be  caused  by  defective
migratory  activity  of  PMNs  to  bacterial  chemoat-
tractants as demonstrated by fMLP.
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Introduction
A  2–10  times  increased  susceptibility  for  bacterial
infections1–5 has  been  proposed  in  patients  with
rheumatoid  arthritis  (RA). This  has  been  primarily
attributed to immunosuppressive treatments widely
used  in  RA.  Other  authors  believe  that  RA  itself
predisposes to infectious diseases.6
Polymorphonuclear  leukocytes  (PMN)  belong  to
the first line of nonspecific cellular defense against
microbiological organisms. Their failure can lead to
life threatening infections as demonstrated by inher-
ited disorders like Kostmann syndrome. Some studies
have  shown  impaired  PMN  function  in  RA
patients7–11 whereas  others  have  failed  to  confirm
these findings.12–15 These controversial studies may
be  the  result  of  different  experimental  designs.
Chemotaxis of PMN has usually been investigated on
separated cell preparations. A recent assessment has
shown that the separating procedure itself causes a
PMN sub-lethal injury,16 which may lead to artefacts
in the migration assay. Therefore, the activation state
of  PMNs  is influenced to  an unforeseeable degree.
Whole  blood  samples  have  been  shown  to  be
advantageous  to  separated  cell  preparations  in  the
examination  of  PMN  migration.16,17 Fresh  whole
blood preserves the genuine priming state of PMNs to
a high extent. To our knowledge, migration of PMNs
in such a whole blood assay has not been investigated
thoroughly in RA.
In our ex vivo migration assay N-formyl-methionyl-
leucyl-phenylalanine (fMLP) a bacterial  chemotactic
peptid was used in a solid form. This reagent is similar
to  lipopolysaccharide  in  stimulating  recruitment  of
PMNs to inflammatory sites and its activity has been
demonstrated in different assays.
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Mediators of Inflammation, 7, 19–23 (1998)We  report  on  spontaneous  and  chemoattractant
directed neutrophil migration using a recently descri-
bed whole blood membrane filter assay which  is a
sensitive  and  diagnostically  predictive  method  to
estimate the original priming state of blood PMNs in
juvenile RA.17
Patients and Methods
Between one and 13 fresh whole blood samples (a
total of 68 samples) were collected from each of 15
patients (14 females, one male; mean age 60.0 ± SEM
10.9  years,  range  35–72  years)  with  RA  defined
according to the 1987 ARA criteria. Migration tests
were performed in different states of disease activity
and compared with reactions of 64 healthy controls
(25  females,  39  males;  mean  age 24.0  ±  SEM 24.1
years,  range  3  weeks  to  92  years).  In  the  control
group juveniles and adults without any clinical and
chemical signs of inflammation were included.
PMN migration was measured in fresh whole blood
by  a  novel  membrane  filter  device  as  previously
described in detail  by  Egger  and  coworkers.17 The
migration  chamber  consisted  of  a  cellulose  nitrate
membrane  filter  of  3mm  pore  size  and  140mm
thickness.  In  the  directed  (stimulated)  migration
experiments  a  chemoattractant  depot  containing
fMLP was attached. Unstimulated experiments lacked
fMLP . A circular plastic container was attached to the
membrane  filter.  Fresh  whole  blood 1:3  diluted in
Hanks’s balanced salt solution prewarmed to 37°C,
PMNs migrated from the blood suspension into the
membrane  filter.  PMNs  were  fixed,  stained  and
counted  under  the  microscope  as  described  else-
where.17The counting was performed in consecutive
steps of 10m m thickness indicating the PMN distribu-
tion throughout the whole depth of the filter. Results
were  evaluated  by  the  following  ‘migration  para-
meters’: (a) absolute number of migrant PMNs (PMN/
mm2),  (b)  percentage  of  PMNs  migrated  from  the
blood total into the filter (total migration index, TMI),
(c) the distance (mm) half the migrating PMNs had
covered within the filter (distribution characteristic,
DC) and (d) the product of TMI and DC (neutrophil
migratory  activity,  NMA),  expressing  the  migratory
capacity  of a PMN collective. Reactions referred to
the chemoattractant fMLP (stimulated conditions) and
to blanks (unstimulated conditions). Each experiment
was performed in triplicate.  Results in RA patients
were compared with those in healthy controls.
PMN  numbers  per  microlitre  of  blood  and PMN
numbers counted in the filters were loaded directly
onto a computer. A program calculated and printed
the migration parameters and plotted a distribution
diagram of the indices versus the counting layers. A
detailed  description  of  calculations  has  been  pub-
lished  previously.17 Statistical  analysis  was  carried
out  using  paired,  unpaired  and  one-sided  t-test,
Welsh test, analysis of variance (ANOVA) and linear
correlations.  Results  are  presented as  mean  ±  SEM
and  are  said  to  be  significant  at  P <  0.05  if  not
specified  otherwise.  Gaussian  distributions  were
ascertained  by  Chi-squared  test.  For  comparison
between  RA  patients  and  controls  the  appropriate
values were matched.
Results
PMN migration parameters TMI and DC in RA patients
compared with healthy controls are shown in Table 1.
In  the  control  group  fMLP  did  not  influence  the
absolute  number  of  migrant  PMNs  (unstimulated:
1238 ± 58 PMN/mm2; stimulated: 1272 ± 62 PMN/
mm2) and the percentage of migrating  cells (TMI).
Blood  PMNs,  ready  to  migrate,  penetrated  signifi-
cantly deeper into the filters under the influence of
fMLP than in blanks. DC values increased from 16.1 ±
0.6 to 18.0 ± 0.7m m after stimulation (P< 0.01). NMA
as a product of TMI and DC was significantly elevated
from  389.0  ±  18.9  to  442.0  ±  21.7  (P <  0.05)  in
stimulated controls mainly as a result of the increased
penetration depth (Fig. 1).
Blood  PMNs  migratory  activity  of  RA  patients
generally increased compared with healthy controls.
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Table 1. Total migration index (TMI) and distribution characteristic (DC) of blood PMNs in 68 migration tests as described in
Patients and Methods of 15 RA patients compared with 64 healthy controls. The data represent mean values of triplicate
measurements ± SEM in unstimulated  (spontaneous migration) or fMLP-stimulated samples of RA patients and healthy
controls
TMI DC
Controls Unstimulated 24.0 ± 0.8 16.1 ± 0.6
(n = 64) Stimulated 24.6 ± 0.9 ** 18.0 ± 0.7
** **
RA patients Unstimulated 28.6 ± 0.9 ** 22.6 ± 1.1
(n = 68) Stimulated ** 26.1 ± 0.9 22.9 ± 0.8
**P < 0.01.Unstimulated and stimulated PMN migratory indices
were  significantly  higher  than  in  healthy  controls
except  the  fMLP  stimulated  DC,  which  remained
unchanged (Table 1, Fig. 1). In blood samples of RA
patients fMLP reduced markedly the PMN responsive-
ness. fMLP-stimulated values of PMN/mm2 (unstimu-
lated: 1954 ± 87 PMN/mm2; stimulated: 1799 ± 93
PMN/mm2; P < 0.01), TMI (unstimulated: 28.6 ± 0.9% ;
stimulated: 26.1 ± 0.9%; P < 0.01) and NMA (unstimu-
lated: 669.0  ±  45.0;  stimulated: 600.0  ±  30.0;  P <
0.05) were significantly lower than those after sponta-
neous migration. Only the DC (unstimulated: 22.6 ±
1.1  m m;  stimulated:  22.9  ±  0.1m m)  showed  no
differences  between  stimulated  and  unstimulated
conditions.
A  five-step  grading  to  determine  disease  activity
(DAC) was used (five disease stages 0 = quiescent to
4 =  maximum  activity). The  number  of patients in
each  one  of  the  categories  0  to  4  was:  DAC  0:  9
patients;  DAC  1:  14  patients;  DAC  2:  18  patients;
DAC 3: 15 patients; DAC 4: 12 patients. Correlations
between disease activity and conventional or experi-
mental RA parameters are shown in Table 2. Disease
activity  calculated  by  ANOVA  of  stimulated  and
unstimulated  values  of TMI,  DC  and  NMA  did  not
significantly  influence  PMN  reactivity.  In  contrast,
the  number  of  circulating  PMNs  increased  with
disease activity, an effect transferred to the parame-
ter  PMN/mm2 essentially  influenced  by  the  PMN
blood counts.
Discussion
The  long-term  prognosis  of  RA  varies  from  mild
disability  of  peripheral  joints  to  mortality  rates  in
severe  cases  similar  to  that  of  patients  with  three-
vessel  coronary  artery  disease  or  malignancies.18
Results  of  a  25-year  prospective  study  of  209  RA
patients  showed  a  3.7-fold  increased  proportional
mortality  ratio  relative  to  the  general  population,
standardized for age and sex.4 This excess mortality
was  associated  with  an  increased  susceptibility  to
bacterial infections. Suzuki et al.19 found infections as
a cause of death in 24%  of 81 autopsied RA patients
compared with only 1.5% of 243 non-RA patients. It
has been argued that this excess mortality might be in
part a consequence of the disease per se.20
Circulating blood PMNs in RA are considered to be
hyperactive because of their increased chemilumines-
cence  response  compared  with  those  of  healthy
subjects.21 Activated PMNs emigrate from the blood-
stream  and  migrate  into  articular  joints  where  the
cells are occupied with phagocytosis and the release
of soluble inflammatory factors.22 Increase of PMN
locomotion  speed  and  directed  migration  are  an
essential part of the non-specific endogenous defence
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FIG. 1. Neutrophil migratory activity (NMA) of blood PMNs in
68 migration tests as described in Patients and Methods of 15
RA patients compared with 64 healthy controls. The data
represent mean values of triplicate measurements ± SEM in
unstimulated  (spontaneous  migration)  or fMLP-stimulated
(directed  migration)  samples  of  RA  patients  and  healthy
controls. *P < 0.05, **P < 0.01.
Table 2. RA disease activity scoring versus conventionala and
experimentalb RA parameters. Regression coefficient values
between  disease  activity  and  parameters  are  shown  if
significant
Parameter Disease activity score
regression
coefficients
P-values
Conventional
ESR 0.5573 < 0.001
CRP 0.3831 < 0.01
PMN/m l 0.443 < 0.001
HGB -0.2424 < 0.05
PLT 0.3704 < 0.01
RF NS NS
Experimental unstimulated
(blank control conditions)
PMN/mm2 0.4952 < 0.001
TMI NS NS
DC NS NS
NMA NS NS
Experimental fMLP stimulated
PMN/mm2 0.4284 < 0.001
TMI NS NS
DC NS NS
NMA NS NS
aErythrocyte  sedimentation  rate  (ESR),  C-reactive  protein  (CRP),
blood  PMNs  (PMN/m l),  haemoglobin  (HGB),  platelets  (PLT)  and
rheumatoid factor (RF).
bNumber of PMN immigrants per  one  square millimeter standard
counting area (PMN/mm
2), total migration index (TMI), distribution
characteristic  (DC)  and  neutrophil  migratory  activity  (NMA)  as
described in Patients and Methods.
NS = not significant, fMLP = N-formyl-methionyl-leucyl-phenylalanine.system.  Experiments  on  infection-prone  children
showed  defects  of  the  PMN  chemotactic  response
which correlated to the severity of their infections.23
Reviewing  the  literature  we  found  contradictory
reports of depressed,7–11 normal12–14 or increased15
chemotaxis of peripheral blood PMNs in RA patients.
Differences in the technique and the isolation proce-
dure, which might be detrimental to the function of
blood PMNs as shown by Rice and Bignold16 may help
to explain the controversy.
To  avoid  this  kind  of  influence  on  PMNs,  we
established an experimental design that conserves the
dynamic activation of PMNs. The use of diluted fresh
whole blood instead of purified leukocyte fractions
offers not only fast and inexpensive processing but,
even more important, preserves the cells in or near
their genuine priming state since they are not affected
by isolation procedures.
Our results confirm the findings of Turner et al.10
This group has demonstrated a significant defect in
the ability of RA PMNs to orientate in the direction of
a  bacterial  chemoattractant  gradient.  Additionally
Goddard  et al.8 found  a  significant  reduced chem-
otactic index, which was calculated by the difference
of the mean value for random migration and the mean
value  for  directed  migration  with  the  results
expressed in a  percentage  of  the  control value.  In
contrast to this group, we were able to demonstrate a
difference  in  the  random  motility  of  RA  PMNs
compared with controls.
In our results PMNs of RA patients showed a higher
migratory  activity  with a concomitant inhibition of
their reactivity  towards  fMLP . However, the lack of
fMLP to stimulate PMNs of RA patients like PMNs of
healthy controls indicates that in these patients the
readiness of blood PMNs to migrate is at least partially
inhibited.  Itala  and  coworkers24 also  showed  reac-
tions of PMNs of healthy controls to be stimulated by
fMLP . They too found significant impairment in fMLP
induced  PMN  migration  in  patients  with  chronic
lymphocytic  leukaemia  and  a  history  of  infections.
Therefore, a migration assay using fMLP as chemoat-
tractant  seems  to  be  a  suitable  model  to  study
susceptibilities to infectious diseases.
At present it is not known whether these functional
anomalies of PMNs in RA patients are secondary to
the disease without further pathogenetic implications
or whether these anomalies are a possible pathophy-
siologic explanation for the increased rate of septic
complications in these patients. In RA patients PMNs
are directed to the inflammatory site by chemokines
such as interleukin-8 and transforming growth factor
b .25 These  factors  are  detectable  in  synovium  and
blood serum of RA patients but not in healthy controls
and  may  be  partly  responsible  for  the  enhanced
migratory activity of PMNs in our experiments in RA
patients. Tumour necrosis factor alpha (TNFa ), persis-
tently found in blood serum of RA patients,26 was able
to decrease fMLP induced PMN chemotaxis in an in
vitro migration  assay.27 In  another  study  fMLP
reduced  PMN  migration  in  early  stages  of  patients
with  thermal  injury28 where  high  levels  of  proin-
flammatory cytokines such as TNFa are produced. All
these  data  implicate  a  pivotal  role  of TNFa in  the
decreased  migratory  response  of  fMLP  stimulated
PMNs  observed  in  RA  patients.  Inhibitory  factors
different  from  TNFa may  also  contribute  to  the
impaired  fMLP  induced  PMN  migration  in  RA.  A
chemokinetic inhibitory factor is expressed by B cells
in chronic lymphatic leukaemia patients with a higher
propensity to infections.29 B cells are activated in RA
and  fMLP  may  induce  the  production  of  such  a
chemokinetic  inhibitory factor  in our  whole  blood
membrane filter assay explaining the reduced readi-
ness of blood PMNs to migrate.
Recruitment of PMNs to the inflammatory site in
RA  is  thought  to  be  driven  by  proinflammatory
cytokines  mainly  secreted  from  T  cell  activated
macrophages.25 On the other hand, the capability of
fMLP , as a bacteria derived peptide, to enhance PMN
migratory activity seems to be a good model for an
acute bacterial infection in vivo. Impaired response
to fMLP stimulated PMNs demonstrated in our experi-
ments may highlight what is happening to PMNs in a
chronically activated immune system after challenge
to bacterial infection. Further studies are encouraged
to uncover mediators of inflammation which regulate
the state of activation of PMNs and contribute to the
diminished migration of PMNs in RA.
In conclusion, we have found an abnormal directed
migration of PMNs to the bacterial chemoattractant
fMLP in RA patients in vitro. Our results may help to
elucidate  the  underlying  mechanism which  lead  to
the clinically observed increased rate of septic com-
plications in RA.
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